Cox Troy 4

What Happened

• Troy Cox, a director of Standard BioTools, was granted a total of 275,039 restricted stock units (RSUs) effective 2026-06-18. The filing shows 99,116 shares and an additional 175,923 derivative RSUs, all reported with a $0.00 acquisition price (no cash exchanged).

Key Details

• Transaction date: 2026-06-18; Form 4 filed: 2026-06-23 (filing occurred 5 days after the transactions).
• Grant amounts: 99,116 RSUs (reporting code A) and 175,923 RSUs reported as a derivative acquisition (total 275,039 RSUs).
• Reported acquisition price: $0.00 (awarded, not purchased); total cash value at grant: $0.
• Shares owned after transaction: not specified in the information provided.
• Footnotes: F1 — RSUs vest in full on the earlier of June 18, 2027 or one day prior to the company’s next annual meeting of stockholders, subject to continued service; each RSU converts to one share upon vesting. F2 — references an option vesting schedule (12 equal monthly installments beginning July 18, 2026); this footnote appears in the filing but no option exercise/grant is listed among the A transactions reported here.

Context

• These are awards (not open-market purchases or sales); awards are common for compensation and do not by themselves indicate the insider is buying or selling shares. The derivative designation means the larger grant represents units that will convert to common stock upon vesting per the RSU terms. The Form 4 was filed after the transaction date; investors tracking insider timeliness may note the filing date relative to the transaction date.